Search
Influenza B virus B/Austria/1359417/2021 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB16923ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes
Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB18750ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes
Influenza A virus A/District of Columbia/27/2023 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB22669ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes
Influenza A virus A/Victoria/800/2024 CVR-289 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB22671ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes
Influenza A virus A/Perth/722/2024 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB31654ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes
Pipequaline
go.drugbank.com/drugs/DB13991ExperimentalDue to these differences, this drug is classified as a nonbenzodiazepine anxiolytic.
Epcoritamab
go.drugbank.com/drugs/DB16672ApprovedInvestigational[L46516,L46556] In September 2023, epcoritamab was also approved in the EU for the same indication.
Osimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalApproximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells.
Horse chestnut
go.drugbank.com/drugs/DB13195InvestigationalUnprocessed horse chestnut seeds contain a toxin called esculin (also spelled aesculin) that increases the risk of bleeding due to anticoagulant actions.
Nateglinide
go.drugbank.com/drugs/DB00731ApprovedDue to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose.